semaglutide eye sight Wegovy Vision Loss Lawsuit [2026 Update] Semaglutide linked to sight-threatening eye

Retatrutide Retatrutide is the newest triple agonist (GLP-1/GIP/glucagon)

doi: 10.1177/20552076251365086, 30

The consolidated cases in MDL 3094 include claims involving multiple GLP-1 receptor agonist medications: Ozempic and Wegovy (semaglutide) manufactured by Novo Nordisk Rybelsus (oral semaglutide) manufactured by Novo Nordisk Mounjaro (tirzepatide) manufactured by Eli Lilly Trulicity (dulaglutide) manufactured by Eli Lilly Saxenda (liraglutide) recently added to the MDL in December 2024 Unlike a traditional class action where all plaintiffs receive identical settlements, the MDL process for Ozempic cases allows for individualized compensation based on injury severity, duration of use, and specific damages incurred

7 Second Nature's Mounjaro and Wegovy programmes Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes

In addition, patients prescribed semaglutide may have had greater engagement with the health care system and more complete longitudinal follow-up, which could increase the likelihood of NAION detection compared with control patients